Search

Your search keyword '"French National Agency for Research on AIDS and Viral Hepatitis"' showing total 57 results

Search Constraints

Start Over You searched for: Author "French National Agency for Research on AIDS and Viral Hepatitis" Remove constraint Author: "French National Agency for Research on AIDS and Viral Hepatitis" Publisher hal ccsd Remove constraint Publisher: hal ccsd
57 results on '"French National Agency for Research on AIDS and Viral Hepatitis"'

Search Results

1. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study

2. Novel role of UHRF1 in the epigenetic repression of the latent HIV-1

3. Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants

4. Initiating antiretroviral treatment early in infancy has long-term benefits on the HIV reservoir in late childhood and adolescence

5. TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women

6. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

7. SUGT1 controls susceptibility to HIV-1 infection by stabilizing microtubule plus-ends

8. Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort)

9. HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry

10. Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection

11. Intimate partner violence against HIV-positive Cameroonian women: Prevalence, associated factors and relationship with antiretroviral therapy discontinuity-results from the ANRS-12288 EVOLCam survey

12. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus RNA Replication

13. Profil, pratiques à risques et besoins des personnes qui injectent du sulfate de morphine : Résultats de l'étude ANRS-AERLI

14. Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS CO-13 HEPAVIH Cohort)

15. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

16. Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells

17. Treatment interruption in HIV-positive patients followed up in Cameroon's antiretroviral treatment programme : individual and health care supply-related factors (ANRS-12288 EVOLCam survey)

18. Interaction study between HCV NS5A-D2 and NS5B using 19F NMR

19. Impact of an educational intervention on risks associated with drug injection, and on psychosocial factors (PSF) involved in initiating and maintaining new health behaviors over time

20. Changes in supervised drug-injecting practices following a community-based educational intervention: A longitudinal analysis

21. NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy

22. Self-Reported Bothersome Symptoms Across Different Socioepidemiological Groups of People Living With HIV Attending French Hospitals: Results From the ANRS-VESPA2 Survey

23. Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients

24. Clinical development of hepatitis C virus host-targeting agents

25. The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients

26. Decrease in self-reported offences and incarceration rates during methadone treatment: A comparison between patients switching from buprenorphine to methadone and maintenance treatment incident users (ANRS-Methaville trial)

27. Detectable HIV-RNA in semen of HIV controllers

28. Characterization of the interaction between the HIV-1 Gag structural polyprotein and the cellular ribosomal protein L7 and its implication in viral nucleic acid remodeling

29. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort]

30. A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients

31. What Level of Risk Compensation Would Offset the Preventive Effect of Early Antiretroviral Therapy? Simulations From the TEMPRANO Trial

32. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus–coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13–HEPAVIH Cohort

33. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus

34. Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized Clinical Trial

35. Immune activation in HIV infection: what can the natural hosts of simian immunodeficiency virus teach us?

36. Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-α Production in Women

37. The genome of the vervet ( Chlorocebus aethiops sabaeus )

38. Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro

39. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial

40. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission

41. Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans

42. Innate Immune Responses and Rapid Control of Inflammation in African Green Monkeys Treated or Not with Interferon-Alpha during Primary SIVagm Infection

43. Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam

44. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design

45. Impact of HCV treatment and depressive symptoms on adherence to HAART among coinfected HIV-HCV patients: results from the ANRS-CO13-HEPAVIH cohort

46. Impact of HCV treatment and depressive symptoms on adherence to HAART among coinfected HIV-HCV patients: results from the ANRS-CO13-HEPAVIH cohort.: HCV treatment and adherence to ART

47. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing

48. Will it be possible to live without antiretroviral therapy?

49. CD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection

50. Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults

Catalog

Books, media, physical & digital resources